November 2005 Archives
Cord Blood America CEO, Interviewed By World Talk Radio, Explains Why Company Outperforms Competitors
LOS ANGELES, Nov. 7 - Cord Blood America, Inc. (OTC Bulletin Board:CBAI), the umbilical cord blood stem cell preservation company which is focused on bringing the life saving potential of stem cells to families nationwide, today in a World Talk Radio interview with Chairman and CEO Matthew L. Schissler said the Company is outpacing the industry with its performance year after year.
...Posted on November 29, 2005 12:48 PM | Comments (0)
StemCells, Inc. Receives Clearance to Initiate Phase I Clinical Trial of Neural Stem Cells to Treat Batten Disease
First-Ever FDA-Approved Trial to Transplant Human Neural Stem Cells
PALO ALTO, Calif., (October 20, 2005) – StemCells, Inc. (NASDAQ: STEM) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase I safety and preliminary efficacy trial of the Company’s proprietary human neural stem cell product ─HuCNS-SC ™─ to treat Batten disease. Batten disease is a rare, fatal genetic disorder that affects the central nervous system of children. This is the first-ever FDA-approved clinical trial to use a purified composition of human neural stem cells as a potential therapeutic agent in humans.
...Posted on November 4, 2005 01:17 PM | Comments (0)
CRYO-CELL Signs Exclusive License to Market New Stem Cell Service
Innovative Offering Will Bundle Novel Placental Stem Cells With U-Cord(R)Service for Unique Industry Position
OLDSMAR, Fla., Oct. 17 – CRYO-CELL International, Inc. (OTC BB: CCEL) announced today that it has signed an exclusive Strategic Relationship Agreementwith Plureon Corporation, a private biotechnology company, to provide collection andpreservation of Plureon's proprietary stem cells. Under the terms of the agreement, CRYO-CELLwill develop the proprietary methodology to collect, process and cryogenically preserve PlureonStem Cells (PSCs) collected from placental tissue at the time of birth.
...Continue reading "CRYO-CELL Signs Exclusive License to Market New Stem Cell Service"
Posted on November 4, 2005 01:16 PM | Comments (0)
Stem Cell Cure for Peripheral Vascular Disease on the Horizon
Bangkok - TheraVitae, Ltd has announced its intention to begin clinical trials using autologous adult stem cells to treat patients suffering from Peripheral Vascular Disease (PVD).
The trials are slated for November 2005 and will be held in conjunction with the Vascular Centers at both Bangkok General Hospital and Chaophya Hospital .
...Continue reading "Stem Cell Cure for Peripheral Vascular Disease on the Horizon"
Posted on November 4, 2005 01:03 PM | Comments (0)
GE Healthcare and ThermoGenesis Announce Worldwide Distribution Agreement and R&D Collaboration
CHALFONT ST. GILES, England and RANCHO CORDOVA, Calif., Oct. 14 - GE Healthcare, a unit of General Electric Company (NYSE: GE), and ThermoGenesis (Nasdaq: KOOL) announced today a global distribution agreement and R&D partnership. The companies will jointly present the AXP(TM) AutoXpress Platform, a closed and automated system for harvesting mononuclear cells (MNC) from cord blood, at the AABB Annual Meeting in Seattle, Washington on October 17th and 18th.
This cell population contains the hematopoietic stem cells used to treat more than 60 malignant, genetic and acquired diseases, such as leukemia, lymphoma, sickle cell anemia, thalassemia and immunodeficiency.
...Posted on November 3, 2005 02:26 PM | Comments (0)
New Johns Hopkins/KN Study Defines Gray Areas in Public Views on Stem Cell Research
Congressional Leaders Have Been Briefed on Results; Pew Charitable Trusts Are Major Sponsor
MENLO PARK, Calif., Oct. 14 - A new Johns Hopkins University study - conducted by Knowledge Networks - brings a nuanced understanding to policy makers' understanding of views on the polarizing issue of stem cell research.
The study was developed by the university's Genetics and Public Policy Center and supported by The Pew Charitable Trusts in partnership with the Phoebe R. Berman Bioethics Institute at Johns Hopkins.
...Posted on November 3, 2005 02:21 PM | Comments (0)
Plureon Corporation Announces Diabetes Research and Development Agreement With BD
WINSTON-SALEM, N.C., Oct. 14 - Plureon Corporation ("Plureon") today announced that it has entered into an agreement with BD (Becton, Dickinson and Company) in the field of diabetes research and development using Plureon's platform stem cell technology. Plureon's stem cells may be obtained from placental tissues that are usually discarded as medical waste after birth.
Under the agreement, BD will sponsor Plureon's research efforts for up to three years and will be responsible for further development of the technology. Plureon retains rights to provide future manufacturing and medical education support to BD.
...Continue reading "Plureon Corporation Announces Diabetes Research and Development Agreement With BD"
Posted on November 3, 2005 02:02 PM | Comments (0)
Robinson Joins Ixion as Controller
ALACHUA, Fla., Oct 13, 2005 - Victor G. Robinson has joined Ixion Biotechnology as controller.
Formerly a senior auditor with Bruno & Tervalon LLP, CPAs, in New Orleans, Robinson is responsible for interpreting and reporting Ixion's financial and accounting information, analyzing capital expenditure proposals and long range planning.
The Dillard University, New Orleans, accounting graduate is also responsible for managing internal and external accounting functions and the Company's relationships with independent auditors.
...Continue reading "Robinson Joins Ixion as Controller"
Posted on November 3, 2005 01:49 PM | Comments (0)
Alliance for Stem Cell Research Supports Motion to Dismiss Prop 71 Lawsuits
SANTA MONICA, Calif., Oct. 12 - The Alliance for Stem Cell Research, a nonprofit organization dedicated to advancing the field of stem cell research through education and patient advocacy, announced its support for a "motion for judgment on the pleadings" being filed today by the State of California, the California Institute for Regenerative Medicine, and other state defendants in response to two lawsuits that challenge Proposition 71, California's $3 billion stem cell research initiative.
Continue reading "Alliance for Stem Cell Research Supports Motion to Dismiss Prop 71 Lawsuits"
Posted on November 3, 2005 01:38 PM | Comments (0)
Citizens' Initiative Effort Launched to Protect Stem Cell Research and Cures in Missouri
Statewide Ballot Measure is the First in U.S. Designed to Protect Patients' Rights to Receive Stem Cell Therapies and Cures
JEFFERSON CITY, Mo., Oct. 11 - A coalition of patient advocacy groups, medical organizations and concerned citizens today launched an effort to seek voter approval of a state constitutional amendment designed to ensure that any stem cell research, therapies and cures permitted by federal law will continue to be allowed in Missouri. The amendment, called the Missouri Stem Cell Research and Cures Initiative, is the first state measure in the nation that would clearly protect the right of patients to have their diseases and injuries treated with any stem cell cures allowed by federal law.
...Posted on November 3, 2005 01:29 PM | Comments (0)
BioE Selected as a 2005 Tekne Award Finalist
Annual award program honors companies and individuals who have shown superior technology innovation and leadership in Minnesota
BioE, Inc., a biomedical company providing enabling non-embryonic, human stem cells, announced today the Minnesota High Tech Association (MHTA) and Minnesota Technology, Inc. (MTI), in partnership with Medical Alley/MNBio, selected it as a 2005 Tekne Award finalist in the emerging biotechnology company category. The Tekne Awards, now in their sixth year, honor companies and individuals who have shown superior technology innovation and leadership in Minnesota.
...Continue reading "BioE Selected as a 2005 Tekne Award Finalist"
Posted on November 3, 2005 01:17 PM | Comments (0)
Osiris Launches a Phase II Clinical Trial for Severe Graft vs Host Disease
BALTIMORE, Maryland October 12, 2005 Osiris Therapeutics, Inc. announced today that it has received clearance from the United States Food and Drug Administration (FDA) to conduct a Phase II trial to evaluate the safety and effectiveness of its lead investigational stem cell drug, Prochymal, for the rescue of patients with the most severe form of acute graft vs. host disease (GVHD).
So called treatment-refractory GVHD occurs when patients fail to respond to conventional therapy and is fatal in more than 80% of cases.
...Continue reading "Osiris Launches a Phase II Clinical Trial for Severe Graft vs Host Disease"
Posted on November 3, 2005 01:05 PM | Comments (0)